Hypertension accounts for a substantial amount of preventable health loss attributable to modifiable risk factors, and its prevalence increases with age. 1 With the aging of the population, it has become a global priority to control blood pressure (BP) levels according to the best available evidence. However, inconsistent results from clinical trials and observational studies have led to discrepant hypertension definitions among scientific societies, including the American Heart Association (AHA), the American College of Physicians (ACP) and the European Society of Cardiology (ESC). [2] [3] [4] Particularly for older patients, the cut-off values for hypertension in the ACP and ESC guidelines are 150/90 mmHg and 140/ 90 mmHg, respectively. Meanwhile, the latest AHA hypertension guideline 2 lowered the threshold of stage 1 hypertension to 130/80 mmHg. This decision was based on a systematic appraisal of randomised clinical trials, 2, 5 indicating that hypertension treated to the new goal can reduce the risk of major cardiovascular events such as myocardial infarction, stroke and heart failure.
Since its inception in 2017, the rigorous modification of BP thresholds in the AHA guideline has stimulated intense debate. 6, 7 Most of the criticism regarding the lowering of the BP threshold is based on the potential risks of overdiagnosis and overtreatment. With 130/80 mm Hg as a new cut-off value for stage 1 hypertension, more individuals would be identified as prevalent cases, and consequently more would require antihypertensive therapy. This could be particularly challenging when implementing the new AHA guidelines in the elderly, given the potential increase in the healthcare costs 8 and the putative side effects of antihypertensive treatments related to older age. 7 Against the overtreatment arguments, the AHA guideline indicates that based on the cardiovascular risk score calculation, only a small proportion of newly diagnosed patients would require medical treatment. The majority would control BP values through lifestyle modifications, which would imply the development of comprehensive preventive strategies targeting cardiovascular risk factors. Still, the implications of the current AHA guideline remain to be further explored in real life settings, beyond the clinical trials that originated the existing recommendations.
In this issue of the European Journal of Preventive Cardiology, Na Liu et al. investigated the association of the new BP criteria with all-cause and cardiovascular disease (CVD) mortality, based on the pooled data from three prospective Chinese cohorts. 9 In a total population of 154,000 participants, the prevalence of stage 1 hypertension was 45.6%. Stage 1 hypertension was associated with an increased risk of mortality due to CVD, ischaemic heart disease and cerebrovascular disease. Importantly, 27.4% and 9.8% of CVD deaths could be prevented if stage 1 hypertension was eliminated among adults younger and older than 65 years, respectively. However, as the authors acknowledge, the proportion of patients that would require antihypertensive medications according to the new AHA guideline could not be calculated in this setting due to the lack of available data on the baseline cardiovascular risk score. Of note, Na Liu et al. 9 found that the association of stage 1 hypertension with mortality was stronger among participants younger than 65 years of age and was attenuated with increasing age. In line with the current AHA recommendations, it was concluded that for individuals younger than 65 years of age and without pre-existing CVD, a comprehensive management of BP to less than 130/80 mmHg (by way of lifestyle modifications and home BP monitoring) could contribute to the prevention of CVD mortality. This is also supported by other prospective studies performed in multi-ethnic populations, reporting that the risk of CVD for younger adults diagnosed with stage 1 hypertension is higher compared to those with normal BP values. 10 On the other hand, the evidence for older patients is not as consistent as it is for younger patients, and this may be attributable to the large clinical heterogeneity within the elderly population. Hence, some previous studies have shown that the association of BP with CVD mortality is attenuated with older age and poorer health status, while additional evidence supports the benefits of lowering BP in older people with few comorbidities and preserved autonomy. 2, 5, 11 In view of the discrepancies among the current guidelines on hypertension, several issues need to be considered by future research in order to facilitate heading towards an agreement. Generally, selected subgroups of older people are excluded from clinical trials due to safety concerns and comorbid conditions, thus limiting the generalisability of the results and making it difficult to obtain definitive evidence to modify the guidelines. To address this, observational studies including large and clinically heterogeneous samples of the general population are needed to explore the potential risk differences by sex, age, comorbidities, functionality and other factors that may explain current inconsistencies. A specialised geriatric assessment, the calculation of aging scores, and a comprehensive evaluation of age-related factors could further contribute to the development of elderly-tailored recommendations for the management of hypertension. Moreover, the recommendations need ultimately to reflect the multidimensional impact of BP trajectories on the overall health of older people. Besides focusing on mortality and CVD, future studies may also need to take into account the role of different BP targets on cognitive decline, physical dysfunction, falls, fractures and quality of life. Given that the utilisation of healthcare resources increases with increasing age, the economic burden of different hypertension guidelines should be also carefully investigated in older patients.
In conclusion, the current available evidence on the management of hypertension indicates that for older patients the strategy of one size fits all does not apply. The concern regarding overdiagnosis is increasing globally, and the possible risks of antihypertensive treatments may outweigh their potential benefits. The lack of consensus in the current guidelines calls for interdisciplinary work among cardiologists and geriatricians, and encourages a careful personalised management of hypertension in older patients. In this context, the development of elderly-tailored recommendations for hypertension could improve the health and wellbeing of older patients.
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